MX2012015102A - Agentes terapeuticos 976. - Google Patents

Agentes terapeuticos 976.

Info

Publication number
MX2012015102A
MX2012015102A MX2012015102A MX2012015102A MX2012015102A MX 2012015102 A MX2012015102 A MX 2012015102A MX 2012015102 A MX2012015102 A MX 2012015102A MX 2012015102 A MX2012015102 A MX 2012015102A MX 2012015102 A MX2012015102 A MX 2012015102A
Authority
MX
Mexico
Prior art keywords
therapeutic agents
azetidinyl
compound
melanin
prophylaxis
Prior art date
Application number
MX2012015102A
Other languages
English (en)
Inventor
Lanna Li
Lars Anders Mikael Johansson
Susanne Doris Margit Boekman-Winiwarter
Marlene Fredenwall
Carl Anders Hogner
Robert Andrew Judkins
Bjoern Christian Ingvar Loefberg
Sverker Vonunge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44514822&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012015102(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2012015102A publication Critical patent/MX2012015102A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Se describen en la presente los compuestos de azetidinilo de la formula (I), según se describió en la presente las composiciones farmacéuticas que comprenden un compuesto de azetidinilo y. un método para el uso de un compuesto azetidinilo en el tratamiento e profilaxis de una enfermedad o condición relacionada son le hormona do concentración de melanina.
MX2012015102A 2010-07-06 2011-07-04 Agentes terapeuticos 976. MX2012015102A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36158510P 2010-07-06 2010-07-06
PCT/GB2011/051256 WO2012004588A2 (en) 2010-07-06 2011-07-04 Therapeutic agents 976

Publications (1)

Publication Number Publication Date
MX2012015102A true MX2012015102A (es) 2013-05-01

Family

ID=44514822

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012015102A MX2012015102A (es) 2010-07-06 2011-07-04 Agentes terapeuticos 976.

Country Status (26)

Country Link
US (1) US8546375B2 (es)
EP (1) EP2590969B1 (es)
JP (1) JP5827683B2 (es)
KR (1) KR20130041177A (es)
CN (1) CN103209979B (es)
AR (1) AR082113A1 (es)
AU (1) AU2011275547B2 (es)
BR (1) BR112013000296A2 (es)
CA (1) CA2802832A1 (es)
CL (1) CL2013000027A1 (es)
CR (1) CR20130005A (es)
CU (1) CU20130004A7 (es)
DO (1) DOP2013000004A (es)
EA (1) EA201291384A1 (es)
EC (1) ECSP13012369A (es)
ES (1) ES2527466T3 (es)
GT (1) GT201300006A (es)
HK (1) HK1182712A1 (es)
MX (1) MX2012015102A (es)
NI (1) NI201200196A (es)
PE (1) PE20130781A1 (es)
SA (1) SA111320581B1 (es)
SG (1) SG186275A1 (es)
TW (1) TW201206916A (es)
UY (1) UY33487A (es)
WO (1) WO2012004588A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
CN104974106B (zh) * 2014-04-04 2019-02-22 浙江普洛康裕制药有限公司 5-烷基-[1,3,4]-噁二唑-2-甲酸烷基酯的合成方法
CN108840812B (zh) * 2018-06-29 2020-08-18 南京富润凯德生物医药有限公司 一种3-(二氟甲基)-3-羟基氮杂环丁烷中间体及其盐的制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4212867A (en) * 1977-03-03 1980-07-15 Philagro 2-Cyano-5-substituted 1,3,4-oxadiazoles and fungicidal compositions containing them
DE3039087A1 (de) 1980-10-16 1982-05-19 Hoechst Ag, 6000 Frankfurt 1-(1,3-dioxolan-2-ylmethyl)-azole, ihre salze, verfahren zu ihrer herstellung und ihre verwendung
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB2184122B (en) 1985-12-17 1989-10-18 Boots Co Plc N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate
EP0619814A1 (en) 1991-12-31 1994-10-19 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
MX9702380A (es) 1995-08-02 1998-02-28 Uriach & Cia Sa J Nuevas carboxamidas con actividad antifungica.
SE0202134D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Therapeutic agents
EP1553089B1 (en) 2002-07-30 2009-09-30 Banyu Pharmaceutical Co., Ltd. Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
EP1593667A4 (en) 2003-02-12 2009-03-04 Takeda Pharmaceutical AMINE DERIVATIVE
US20060293298A1 (en) 2003-04-10 2006-12-28 Bamford Mark J Compounds
GB0400193D0 (en) 2004-01-07 2004-02-11 Astrazeneca Ab Therapeutic agents
WO2005066132A1 (en) 2004-01-07 2005-07-21 Astrazeneca Ab Therapeutic agents i
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
TW200538098A (en) 2004-03-22 2005-12-01 Astrazeneca Ab Therapeutic agents
ATE432926T1 (de) 2004-07-26 2009-06-15 Lilly Co Eli Oxazolderivate als histamin-h3-rezeptor- wirkstoffe, deren herstellung und therapeutische verwendung
SI1805169T1 (sl) 2004-10-18 2009-06-30 Lilly Co Eli Inhibitorji histamin h3 receptorja, njihova priprava in terapevtske uporabe
MX2007007226A (es) 2004-12-17 2007-08-21 Lilly Co Eli Antagonistas receptores novedosos de hormona concentradora de melanina (mch).
AR051802A1 (es) 2004-12-21 2007-02-07 Astrazeneca Ab Heterociclos antagonistas de mchr1
JP2006176443A (ja) 2004-12-22 2006-07-06 Shionogi & Co Ltd メラニン凝集ホルモン受容体アンタゴニスト
BRPI0610907A2 (pt) 2005-05-31 2008-12-02 Astrazeneca Ab composto ou precursores hidrolisÁveis in vivo ou sal farmaceuticamente aceitÁvel do mesmo, mÉtodos de tratamento ou profilaxia de uma doenÇa ou condiÇço na qual a modulaÇço do receptor de mch1 É benÉfica e de tratamento ou profilaxia de doenÇas, composiÇço farmacÊutica, e, uso de um composto
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
DE602006018301D1 (de) * 2005-06-22 2010-12-30 Pfizer Prod Inc Histamin-3-rezeptorantagonisten
WO2007011284A1 (en) 2005-07-15 2007-01-25 Astrazeneca Ab Therapeutic agents
JP2009522354A (ja) 2006-01-06 2009-06-11 アストラゼネカ・アクチエボラーグ 化合物
CA2659155A1 (en) 2006-07-20 2008-01-24 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11.beta.-hsd-1
WO2008020799A1 (en) 2006-08-18 2008-02-21 Astrazeneca Ab Thienopyrimidin-4-one and thienopyridazin-7-one derivatives as mch rl antagonists
CN101541796B (zh) 2006-12-05 2012-11-07 詹森药业有限公司 用于mch-1介导的疾病的取代的二氮杂-螺-吡啶酮衍生物
EP2089397B1 (en) * 2006-12-14 2012-08-29 Eli Lilly & Company 5- [4- (azetidin-3-yl0xy) -phenyl]-2-phenyl-5h-thiaz0l0 [5,4-c]pyridin-4-0ne derivatives and their use as mch receptor antagonists
EP2148931A2 (en) 2007-04-17 2010-02-03 Vertex Pharmaceuticals Incorporated Drug discovery methods for aurora kinase inhibitors
AU2008282156B2 (en) 2007-07-31 2014-07-17 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1H-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
JP2010536818A (ja) 2007-08-22 2010-12-02 エフ．ホフマン−ラ ロシュ アーゲー Ｎｋ３受容体アンタゴニストとしてのピロリジンアリール−エーテル
BRPI0818581A2 (pt) * 2007-10-17 2015-07-21 Sanofi Aventis Carboxamidas n-fenil-bipirrolidina substituídas e uso terapêutico das mesmas
US8124636B2 (en) 2008-04-30 2012-02-28 Hoffmann-La Roche Inc. Imidazolidinone derivatives as 11B-HSD1 inhibitors
JP5780954B2 (ja) * 2008-05-08 2015-09-16 エヴォテック・アクチエンゲゼルシャフト ヒスタミンｈ３受容体アンタゴニストとしてのアゼチジン類及びシクロブタン類
SA110310332B1 (ar) * 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
WO2011019090A1 (en) 2009-08-13 2011-02-17 Mitsubishi Tanabe Pharma Corporation Pyrimidone derivatives used as tau protein kinase 1 inhibitors
US9051296B2 (en) * 2009-11-16 2015-06-09 Raqualia Pharma Inc. Aryl carboxamide derivatives as TTX-S blockers

Also Published As

Publication number Publication date
CU20130004A7 (es) 2013-05-31
CR20130005A (es) 2013-04-17
NI201200196A (es) 2013-10-16
CA2802832A1 (en) 2012-01-12
WO2012004588A2 (en) 2012-01-12
AU2011275547B2 (en) 2015-10-29
ES2527466T3 (es) 2015-01-26
AU2011275547A1 (en) 2013-02-07
JP2013535413A (ja) 2013-09-12
KR20130041177A (ko) 2013-04-24
ECSP13012369A (es) 2013-01-31
US8546375B2 (en) 2013-10-01
PE20130781A1 (es) 2013-07-20
TW201206916A (en) 2012-02-16
BR112013000296A2 (pt) 2019-09-24
CN103209979A (zh) 2013-07-17
SA111320581B1 (ar) 2014-06-17
US20120010189A1 (en) 2012-01-12
DOP2013000004A (es) 2013-04-30
EA201291384A1 (ru) 2013-07-30
UY33487A (es) 2012-02-29
AR082113A1 (es) 2012-11-14
EP2590969A2 (en) 2013-05-15
CN103209979B (zh) 2016-02-10
GT201300006A (es) 2014-11-06
HK1182712A1 (en) 2013-12-06
CL2013000027A1 (es) 2013-03-08
EP2590969B1 (en) 2014-10-15
SG186275A1 (en) 2013-01-30
JP5827683B2 (ja) 2015-12-02
WO2012004588A3 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
IN2015DN01156A (es)
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
MX2012004525A (es) Compuestos.
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
UA115558C2 (uk) Алкілпіримідинові похідні для лікування вірусних інфекцій та подальших захворювань
TN2011000172A1 (en) Therapeutic antiviral peptides
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
MX2011012122A (es) Derivados de tiofeno.
IN2012DN00971A (es)
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2015007796A (es) Derivados de cloro-pirazin carboxamida con actividad bloqueadora sobre los canales de sodio epiteliales.
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
MX2013011589A (es) Metodos y composiciones para tratar enfermedad de parkinson.
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней
MX2015010829A (es) Compuestos terapeuticos y sus usos.
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
GB201213267D0 (en) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
WO2013040227A3 (en) Therapeutic compounds
MX2013003060A (es) Terapia de combinacion para tratar infeccion por hcv.
PH12015500111A1 (en) Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
MX2012013879A (es) Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
MX2011011618A (es) Agentes terapeuticos 713.
MX2012015102A (es) Agentes terapeuticos 976.

Legal Events

Date Code Title Description
FG Grant or registration